Monday, August 31, 2026

MicroVision Stock Plummets 27% In 21 Sessions: Is It Time To Sell?

ViaNews Editorial Team

September 7, 2023

MicroVision Stock Plummets 27% In 21 Sessions: Is It Time To Sell?

(VIANEWS) - MicroVision (MVIS) shares have fallen by 27.36% over 21 sessions, from EUR3.29 to EUR2.39 as of 11:41 AM ET Thursday morning. This decline followed an earlier downward trend as well as three consecutive losses on the NASDAQ index - all contributing factors for its demise by 1.07% to EUR13,724.430 with MicroVision closing at EUR2.46, 70% below its 52-week high of EUR8.20.

About MicroVision

MicroVision, Inc. specializes in the research, development and sale of lidar sensors for automotive safety and autonomous driving applications. Utilizing micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms and software technologies; their laser beam scanning technology stands out as cutting edge innovation. MicroVision Inc has become known for their expertise in micro-display concepts and designs for head-mounted augmented reality (AR) headsets, 1440i MEMS modules supporting AR headsets, interactive display solutions for smart speaker market, as well as Consumer Lidar used for smart home systems. Since 1993, this company has sold its products primarily to original equipment Manufacturers (OEM) with headquarters located in Redmond Washington.

Yearly Analysis

Data indicates that MicroVision stock appears undervalued relative to its 52-week high and overvalued relative to its 52-week low. Anticipated sales growth for this year and next is impressive, suggesting potential for future price increases. Unfortunately, EBITDA figures for MicroVision were not provided - this would be crucial when making investment decisions; we strongly advise conducting additional research on MicroVision's financials as well as overall market conditions before making any definitive investment decisions.

Technical Analysis

MicroVision stock has experienced a decline, as its current price is below both its 50- and 200-day moving averages of EUR4.04 and EUR3.10 respectively. Furthermore, its volume of 754,676 represents 83.89% less than its average volume of 4,367,880. Over the past week, this stock experienced a positive 0.20% intraday variation average, while in terms of month and quarter variations it saw negative 1.75% and positive 4.95% intraday variation averages, respectively. Furthermore, its highest average weekly volatility amplitude has reached 0.60% per week, 3.75% per month, and 4.95% per quarter. MicroVision's stock has fallen below the threshold for overbought-and-oversold conditions according to its stochastic oscillator, an indicator used for tracking overbought/oversold conditions, suggesting it may be undervalued and could possibly rebound soon after being purchased at a reduced price. Investors should bear in mind that past performance does not guarantee future results and must conduct their own due diligence prior to making investment decisions.

Quarter Analysis

According to the data presented, investors should approach this stock with caution. Negative growth estimates for both the current quarter and next indicate that company performance could suffer in the short-term - an alarm bell for investors who favor stocks with positive growth prospects. 4.8% year-on-year quarterly revenue growth over twelve trailing months is an encouraging sign. It shows that revenue has increased, suggesting a healthy and expanding business. Investors should carefully assess a company's growth prospects and overall market conditions prior to making any investment decisions. It may be prudent to delay investing until there is greater clarity regarding future performance of this stock and overall market outlook.

Equity Analysis

MicroVision currently boasts a trailing twelve months EPS of EUR-0.39, signaling to investors that its operations are not yielding profits for them. Furthermore, its Return on Equity (ROE) for this period was negative 63.85% indicating ineffective use of shareholder's capital to generate profits for them. Investors should be mindful that MicroVision is currently not producing profits and effectively utilizing its shareholder's equity, so the company may not represent an attractive investment option at this time. Investors may wish to keep an eye on its future performance as well as any possible changes in management or business strategies which might lead to improved profits or return on equity (ROE). It is also essential to take other factors such as competition position, growth prospects and industry trends into consideration before making investment decisions.

More news about MicroVision (MVIS).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI's Trust Gap: Microsoft-Mistral Ecosystem Expansion Meets a Governance Deficit in Agentic Adoption
Microsoft is deepening its AI platform bet through simultaneous moves — expanding its Mistral partnership (Copilot Studio, Foundry, European infrastructure capacity) and deepening enterprise AI governance ties with Manulife — just as independent research (Google Cloud, VentureBeat, Box) shows enterprises racing toward agentic AI adoption (100% planned within two years) while data access and trust in agent decisions lag badly (average 45% data access, only ~half trust agent outputs). The result is a structural mismatch between platform-vendor momentum and enterprise readiness to actually govern and trust the agents being deployed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
Same entity (Morgan Stanley & Co. LLC), same metric (net_income), same fiscal period (Q1 2026), same observation date (2026-03-31), but vastly different values: $5.567 billion vs. $5.57. These cannot coexist for the same time period. Fact B appears to be a data entry error (possible missing decimal placement: 5.57 should likely be 5,567,000,000 or a per-share figure incorrectly entered as total).
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,257 source documents archived
Query this data → isubstrate.com